The ARHGEF10 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphoblast line, providing a genetically disrupted loss-of-function model for the ARHGEF10 gene. This product features a heterogeneous pool of Jurkat cells carrying targeted gene disruption at the ARHGEF10 locus, enabling investigation of Rho guanine nucleotide exchange factor (GEF) function without clonal selection artifacts. The polyclonal format retains population-level diversity while abolishing ARHGEF10 protein expression, supporting robust functional studies in human T-cell leukemia models.
Jurkat cells are an immortalized T-lymphocyte line originally isolated from the peripheral blood of a 14-year-old male with acute T-cell leukemia. These suspension-growing cells exhibit characteristics of mature T lymphoblasts and endogenously express functional T-cell receptor (TCR) complexes, making them a quintessential model for TCR signaling, activation-induced signal transduction, and leukemic cell biology. Their rapid proliferation, ease of genetic manipulation, and well-characterized signaling networks have established Jurkat cells as a workhorse in immunological and oncological research, particularly for dissecting pathways governing T-cell function, cytokine production, and malignant transformation.
ARHGEF10 encodes a GEF that specifically catalyzes the exchange of GDP for GTP on the small GTPases RhoA and RhoB, thereby activating these molecular switches. Activated RhoA and RhoB propagate signals to downstream effectors including ROCK1, ROCK2, LIMK, cofilin, mDia, and myosin light chain, driving actin cytoskeleton reorganization, stress fiber formation, and focal adhesion maturation. Upstream stimuli such as T-cell receptor engagement, integrin ligation, and chemokine stimulation converge on ARHGEF10-mediated Rho activation, linking extracellular cues to cytoskeletal dynamics. This signaling axis is crucial for cellular processes such as migration, adhesion, and morphological changes, and it intersects with pathways regulating leukocyte transendothelial migration and cancer cell invasion.
In the Jurkat T-cell context, ARHGEF10 disruption is predicted to impair RhoA/B-dependent actin remodeling, thereby attenuating T-cell migratory capacity, adhesion molecule clustering, and potentially TCR-mediated activation events. Given that Rho GTPase signaling is frequently dysregulated in leukemias and contributes to invasive phenotypes, these knockout cells serve as a physiologically relevant platform to dissect the role of ARHGEF10 in malignant T-cell behavior. The availability of a polyclonal knockout population avoids the confounding effects of single-cell clonal variance while retaining the relevance of endogenous Jurkat signaling networks, making it an efficient tool for both mechanistic studies and high-throughput screening.
Typical research applications include quantitative analysis of T-cell migration using Transwell assays, visualization of F-actin organization by immunofluorescence, and RhoA activation pull-down assays to assess GTPase signaling competence. Western blotting for phospho-myosin light chain and RhoA levels, combined with phospho-signaling analysis, allows comprehensive pathway interrogation. The model is also suitable for testing ROCK inhibitor sensitivity and for drug screening workflows targeting the Rho GTPase cascade. For further information, please contact Ascent Research.
